Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.

Autor: Labrie, F.¹ (AUTHOR), Archer, D. F.² (AUTHOR), Bouchard, C.³ (AUTHOR), Fortier, M.³ (AUTHOR), Cusan, L.¹ (AUTHOR), Gomez, J.-L.¹ (AUTHOR), Girard, G.⁴ (AUTHOR), Baron, M.⁵ (AUTHOR), Ayotte, N.⁶ (AUTHOR), Moreau, M.⁷ (AUTHOR), Dubé, R.⁸ (AUTHOR), Côté, I.¹ (AUTHOR), Labrie, C.¹ (AUTHOR), Lavoie, L.¹ (AUTHOR), Berger, L.¹ (AUTHOR), Gilbert, L.⁹ (AUTHOR), Martel, C.¹ (AUTHOR), Balser, J.¹⁰ (AUTHOR)

Publikováno v: Climacteric. Apr2011, Vol. 14 Issue 2, p282-288. 7p. 4 Graphs.

HISTOMORPHOLOGICAL ENHANCEMENT OF THE VAGINAL WALL IN DEHYDROEPIANDROSTERONE-TREATED POST-OVARIECTOMIZED WISTAR RATS.

Autor: Peni, Lis Widodo, Menara Falah, Pilar, Nurdian, Yudha

Publikováno v: Journal of Vocational Health Studies; Jul2024, Vol. 7 Issue 4, p13-19, 7p

Tumor Growth Inhibition in Patients with Prostatic Carcinoma Treated with Luteinizing Hormone-Releasing Hormone Agonists

Autor: Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A. T. A., Comaru-Schally, A. M., Schally, A. V.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 1982 Mar 01. 79(5), 1658-1662.

Externí odkaz: https://www.jstor.org/stable/11837

Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.

Autor: Bouchard, C.¹ (AUTHOR), Labrie, F.² (AUTHOR) Fernand.Labrie@endoceutics.com, Archer, D. F.³ (AUTHOR), Portman, D. J.⁴ (AUTHOR), Koltun, W.⁵ (AUTHOR), Elfassi, É.⁶ (AUTHOR), Grainger, D. A.⁷ (AUTHOR), Ayotte, N.⁸ (AUTHOR), Cooper, T. A.⁹ (AUTHOR), Martens, M.¹⁰ (AUTHOR), Waldbaum, A. S.¹¹ (AUTHOR), Labrie, C.² (AUTHOR), Côté, I.² (AUTHOR), Lavoie, L.² (AUTHOR), Martel, C.² (AUTHOR), Balser, J.¹² (AUTHOR)

Publikováno v: Climacteric. Aug2015, Vol. 18 Issue 4, p590-607. 18p.